Change in Plant-Based Diet Quality Is Associated with Changes in Plasma Adiposity-Associated Biomarker Concentrations in Women

Megu Y Baden,1 Ambika Satija,1 Frank B Hu,1,2,3 and Tianyi Huang1,3

Departments of 1Nutrition, and 2Epidemiology, Harvard TH Chan School of Public Health, Boston, MA; and 3Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA

ABSTRACT

Background: A healthful plant-based diet is associated with lower risk of cardiometabolic diseases. However, it is still unclear whether such benefits are due to its favorable effects on adiposity-associated biomarkers.

Objective: We investigated the associations between biomarkers and 3 plant-based diet indices: an overall plant-based diet index (PDI); a healthful plant-based diet index (hPDI); and an unhealthful plant-based diet index (uPDI).

Methods: In the Nurses’ Health Study II, 831 women [baseline mean age: 45 y; body mass index (BMI, kg/m²): 24.6] were randomly selected from those who provided 2 blood samples in 1996–1999 and 2010–2011 to measure plasma concentrations of adiponectin, leptin, soluble leptin receptor (sOB-R), insulin, retinol-binding protein-4, high-sensitivity C-reactive protein (hsCRP), and interleukin-6 (IL-6). Plant-based diet indices were derived from semiquantitative food frequency questionnaires assessed at each blood collection. Linear mixed models were used to evaluate cross-sectional associations, and general linear models were used to evaluate longitudinal associations.

Results: In cross-sectional analyses with multivariable adjustment including BMI, higher hPDI was associated with lower concentrations of leptin, insulin, and hsCRP, and higher adiponectin and sOB-R concentrations (biomarker differences per 10-point higher hPDI: −7.2%, −10.0%, −13.6%, 3.0%, and 1.9%, respectively; P ≤ 0.025). A higher uPDI was associated with higher concentrations of leptin and insulin (4.4% and 4.8%, respectively; P ≤ 0.048). In longitudinal analyses with multivariable adjustment including weight change, an increase in hPDI (improved plant-based diet quality) was inversely associated with changes in leptin and hsCRP (biomarker changes per 10-point hPDI increase: −7.7% and −17.8%, respectively; P ≤ 0.005), whereas an increase in uPDI (worsened plant-based diet quality) was positively associated with changes in leptin, hsCRP, and IL-6 (10.1%, 13.5%, and 12.4%, respectively; P ≤ 0.021).

Conclusions: Adherence to a healthful plant-based diet is associated with favorable long-term changes in adiposity-associated biomarker concentrations in women. J Nutr 2019;149:676–686.

Keywords: plant-based diet index, biomarker, healthful plant-based diet, obesity, inflammation

Introduction

Obesity has become a worldwide problem, and is a major risk factor for type 2 diabetes (T2D), coronary heart disease (CHD), stroke, and cancer (1–4). Excess visceral fat induces dysregulation of biomarkers that play crucial roles in promoting inflammation and insulin resistance. For example, leptin, adiponectin, and retinol-binding protein-4 (RBP-4) are adipokines secreted from adipose tissues. Positively associated with obesity, leptin acts as a proinflammatory cytokine and its biological activity is partly regulated by soluble leptin receptor (sOB-R), the primary leptin-binding protein in circulation (5, 6). By contrast, adiponectin is inversely associated with obesity, and reduces inflammation and insulin resistance (7–9). RBP-4 is another adipokine that transports retinol (vitamin A) and is elevated among individuals with insulin resistance (10). In addition, the accumulation of abdominal fat has been associated with increasing concentrations of other inflammatory biomarkers such as C-reactive protein (CRP) and IL-6 (11, 12).

Diet is a modifiable factor of obesity and obesity-related diseases, and there has been growing interest in plant-based diets, which have been associated with a lower risk of CHD, T2D, and other cardiometabolic disease (13–17). However, previous studies on plant-based or vegetarian diets are limited...
because they did not differentiate the quality of plant-based foods. For example, certain plant-based foods, such as refined grains and sugar-sweetened beverages, are associated with higher cardiometabolic risk (18–20). To address this, we recently developed 3 plant-based diet indices that reflect the quality of plant-based foods, including an overall plant-based diet index (PDI), a healthful plant-based diet index (hPDI), and an unhealthful plant-based diet index (uPDI). The hPDI captures a high-quality plant-based diet rich in whole grains, fruits, vegetables, and nuts and low in fruit juices, refined grains, and sweets, whereas uPDI represents the opposite. We previously reported that hPDI and uPDI were differentially associated with the risk of T2D and CHD (21, 22). Nevertheless, to what extent a healthful plant-based diet is associated with adiposity-associated biomarkers remained unclear. To our knowledge, no study to date has evaluated the long-term associations between changes in plant-based diet and changes in biomarkers related to cardiometabolic diseases.

Therefore, in this study, we followed healthy US women for an average of 13 y to elucidate whether PDI, hPDI, and uPDI were associated with several biomarkers predictive of cardiometabolic diseases. We hypothesized that improvement in hPDI could be associated with favorable changes in circulating concentrations of adiponectin, leptin, sOB-R, insulin, RBP-4, hsCRP, and IL-6.

**Methods**

**Study population**

The Nurses’ Health Study II was established in 1989 among 116,686 US female registered nurses aged 25–42 y. All women completed a baseline questionnaire, and lifestyle factors and medical history were updated every 2 y. The first blood sample was provided by 29,611 women in 1991, and the FFQ in 2011 was used as the baseline dietary assessment, and the FFQ in 2011 was used as the follow-up assessment (the year close to the second blood measurement).

**Diet assessment**

Beginning in 1991, dietary data were collected every 4 y using a semiquantitative FFQ. Participants reported how often, on average, they had consumed defined portions of the 130 food items over the previous year using 9 response categories, ranging from “never or less than once/month” to “≥ six times/day.” The reliability and validity of the FFQ have been described elsewhere (24, 25). We have previously reported the method to derive the 3 plant-based diet indices from FFQs that differentiate the quality of plant-based foods (21, 22). Briefly, we first created 18 food groups based on nutrients and culinary similarities within the larger categories of healthy plant foods (whole grains, fruits, vegetables, nuts, legumes, vegetable oils, tea/coffee); less healthy plant foods (fruit juices, refined grains, potatoes, sugar-sweetened beverages, sweets/desserts); and animal foods (animal fat, dairy, eggs, fish/seafood, meat, miscellaneous animal-based foods). Food groups were ranked into quintiles, and given positive or reverse scores. For creating a PDI, foods in both plant food groups were given positive scores, and foods in the animal food group were given reverse scores. For the hPDI, foods in the healthy plant food group were given positive scores, and foods in the less healthy plant food group and the animal food group were given reverse scores. For the uPDI, foods in the less healthy plant food group were given positive scores, and foods in the healthy plant food group and the animal food group were given reverse scores. Finally, the 18 food group scores were summed to obtain 3 plant-based diet indices, with a theoretical range of 18 to 90. The FFQ in either 1995 or 1999 (whichever was closer to the first blood measurement) was used as the baseline dietary assessment, and the FFQ in 2011 was used as the follow-up assessment (26).

**Plasma biomarker measurements**

Plasma samples were stored in the vapor phase of liquid nitrogen (LN2) freezers with LN2-rated gasketed screw tops and labels since collection. Plasma biomarker concentrations were measured in the Clinical Chemistry Laboratory at Boston Children’s Hospital. Leptin, sOB-R, RBP-4, and IL-6 were measured by an ultrasensitive ELISA assay (R&D Systems). Total adiponectin was assayed with a quantitative monoclonal sandwich ELISA (Alpco Diagnostics). Insulin was determined by an immunoturbidimetric assay (Dekra Seiken). The mean interassay coefficients of variation (CVs) were 4.9% for leptin, 11.1% for sOB-R, 10.1% for adiponectin, 6.4% for insulin, 10.3% for RBP-4, 1.5% for hsCRP, and 10.8% for IL-6 (23). The free leptin index was calculated as the ratio of leptin to sOB-R to reflect the unbound leptin concentration in circulation (26).

**Covariate assessments**

Date of birth and height were collected at baseline. Biennial follow-up questionnaires updated information on body weight, disease diagnoses, menopausal status, postmenopausal hormone use, and several lifestyle factors including physical activity, alcohol intake, and smoking status. Hypertension and hypercholesterolemia were self-reported by responding to the questions whether the participant had clinician-diagnosed “high blood pressure” or “elevated cholesterol.” We used the covariate information collected concurrently along with the baseline and follow-up FFQs (i.e., either 1995 or 1999 for baseline and 2011 for follow-up).

**Statistical analysis**

All biomarker concentrations and the free leptin index were log-transformed to normalize distributions and then outliers were excluded. Participants were divided into 5 groups according to the quintiles of PDI scores in the cross-sectional analysis, and the quintiles of changes in PDI scores in the longitudinal analysis. We first evaluated the age-standardized distribution of participant characteristics at each blood collection, and the differences between the 2 collections were compared with the use of paired t tests for continuous variables and McNemar’s tests for binary variables. Linear mixed-effect models were used to examine the cross-sectional associations of PDI, hPDI, and uPDI with biomarker concentrations, with an unstructured covariance matrix specified to account for within-person correlations between the 2 time points. Least squares geometric mean concentrations were estimated for each biomarker according to quintiles of the 3 PDIs, and adjusted for time-varying covariates corresponding to each blood
collection, including age (continuous), total energy intake (kcal; in quintiles), alcohol intake (g/day; in quintiles), smoking status (current, past, never), physical activity (metabolic equivalent task hours per week, MET-h/week; in quintiles), menopausal status (premenopausal, postmenopausal, postmenopausal hormone use (current, past, never), hypertension (yes, no), and hypercholesterolemia (yes, no). An indicator variable was also included to differentiate between the first and second blood collection. To elucidate whether associations were independent of obesity, further adjustment for BMI (<20.0, 20.0–24.9, 25.0–29.9, ≥30.0 kg/m²) assessed at each sample collection was made in a separate model. Linear trends were tested by using the median score of each quintile of an index as a continuous variable, and the percentage difference in biomarker concentrations was estimated for every 10-point difference of each index.

In the longitudinal analysis, multivariate general linear regression models were used to examine associations of changes in PDI, hPDI, and uPDI with changes in log-transformed biomarker concentrations between the 2 time points. For each quintile of index changes, least squares geometric mean percentage changes in biomarkers were calculated and adjusted for baseline age, baseline BMI (in quintiles), baseline corresponding PDI (in quintiles), baseline corresponding biomarker concentrations (in quintiles), as well as changes in total energy intake (in quintiles), alcohol intake (in quintiles), smoking status, physical activity (in quintiles), menopausal status, postmenopausal hormone use, hypertension, and hypercholesterolemia. We further adjusted for weight change (in quintiles) in a separate model. Linear trends were tested using the median of each index change within each quintile as a continuous variable. The results were expressed as percentage differences of the percentage changes in biomarker concentrations per 10-point difference in diet index changes, and visualized in a bar graph. Additional analyses evaluated whether the associations were modified by baseline BMI (<25.0, 25.0–29.9, ≥30.0) or weight change (less than the median of 2.7 kg or ≥2.7 kg). The significance of interactions was evaluated by testing the cross product term between changes in the three PDIs and baseline BMI or weight change. Further, we provided information on changes in individual food group intakes according to the quintiles of changes in PDI scores, and the trends were evaluated based on univariate general linear regression models using each index score change as a continuous variable.

Analyses were performed in SAS 9.4 (SAS Institute Inc.), and P values <0.05 were considered significant.

**Results**

Age-standardized characteristics of participants at baseline and follow-up are shown in **Table 1**. At baseline, participants were, on average, 45 y old and their mean BMI was 24.6. During an average follow-up of 13 y (range: 11–15 y), mean plasma concentrations of all biomarkers increased. In addition, participants on average had increased BMI (24.6 to 26.3), alcohol intake (3.9 to 6.2 g/day), physical activity (17.8 to 23.5 MET-h/wk), postmenopausal status (20.6% to 72.1%), prevalence of hypertension (10.9% to 29.4%) and hypercholesterolemia (15.1% to 35.1%), decreased total energy intake (1886 to 1756 kcal/d), current smoking (4.1% to 1.5%), and postmenopausal hormone use (85.5% to 23.9%). About 59.8% of women had an increased PDI score during the follow-up, compared with 46.0% for an increased hPDI score and 15.4% for an increased uPDI score.

Changes in food group intakes by quintiles of changes in PDI, hPDI, and uPDI are shown in **Supplemental Table 1**. Increased PDIs and hPDI were mainly attributed to increased intake of healthy plant foods, whereas increased uPDI was related to decreased intake of healthy plant foods. In general, intake of less healthy plant foods decreased over follow-up, with more remarkable reductions observed for women who had increased hPDI than women who had increased PDI or uPDI. Increased PDI, hPDI, and uPDI were associated with decreased intake of animal foods.

In cross-sectional analyses, higher hPDI was significantly associated with lower leptin (P-trend < 0.001), free leptin index (P-trend < 0.001), insulin (P-trend < 0.001), hsCRP (P-trend < 0.001), and higher adiponectin (P-trend = 0.025) and sOB-R (P-trend = 0.024) after adjusting for all covariates including BMI (**Table 2**). The multivariable-adjusted percentage changes in biomarker concentrations (95% CI) for every 10-point higher hPDI were −7.2% (−11.0, −3.1) for leptin, −8.8% (−13.3, −3.9) for free leptin index, −10.0% (−14.2, −5.6) for insulin, −13.6% (−20.5, −6.1) for hsCRP, 3.0% (0.4, 5.7) for adiponectin, and 1.9% (0.3, 3.7) for sOB-R. By contrast, higher uPDI was significantly associated with a higher concentration of leptin (percentage change for every 10-point higher uPDI: 4.4%, 95% CI: 0.2, 8.6; P-trend = 0.037) and insulin (percentage change for every 10-point higher uPDI: 4.8%, 95% CI: 0.1, 9.7; P-trend = 0.048, **Table 2**). Higher uPDI was significantly associated with a higher free leptin index (P-trend = 0.002) after adjusting for potential covariates without BMI. However, this association was attenuated after adjustment for BMI (P-trend = 0.14). Further, a higher PDI was significantly associated with lower concentrations of insulin (P-trend = 0.007) and hsCRP (P-trend = 0.018) after adjusting for covariates without BMI (**Supplemental Table 2**), but these associations were also attenuated after adjustment for BMI (P-trend = 0.15 for insulin and 0.12 for hsCRP).

The associations between changes in hPDI and uPDI and percentage changes in biomarker concentrations are shown in **Table 3** and **Figure 1**. hPDI increase was significantly associated with smaller increases in leptin (P-trend = 0.005) and free leptin index (P-trend = 0.038), and a larger decrease in hsCRP (P-trend < 0.001) after adjusting for all covariates including weight change (**Table 3**). The multivariable-adjusted percentage differences in biomarker changes (95% CI) for every 10-point hPDI increase were −7.7% (−12.8, −2.4) for leptin, −7.2% (−13.6, −0.4) for free leptin index, and −17.8% (−26.3, −8.4) for hsCRP (**Figure 1**). Similarly, hPDI increase was positively associated with a larger increase in adiponectin prior to adjustment for weight change (P-trend = 0.020), but the association was attenuated after the adjustment (P-trend = 0.23). In contrast, uPDI increase was significantly associated with larger increases in leptin (P-trend < 0.001), free leptin index (P-trend = 0.009), hsCRP (P-trend = 0.021), and IL-6 (P-trend < 0.001) after adjusting for all covariates including weight change (**Table 3**). The multivariable-adjusted percentage differences in biomarker changes (95% CI) for every 10-point uPDI increase were 10.1% (4.2, 16.4) for leptin, 9.7% (2.4, 17.6) for free leptin index, 13.5% (1.9, 26.4) for hsCRP, and 12.4% (5.2, 20.1) for IL-6 (**Figure 1**). Associations of uPDI increase with decreases in adiponectin (P-trend = 0.025) and sOB-R (P-trend = 0.018) were attenuated after adjusting for weight change. There were no significant associations between PDI change and percentage changes in biomarkers (**Supplemental Table 3**). In general, these associations did not differ substantially by baseline BMI and weight change (data not shown).

**Discussion**

In the cross-sectional analyses, we found that a higher hPDI score—a measure of adherence to a high-quality plant-based diet—was significantly associated with lower plasma
Our results provide supporting evidence for the anti-inflammatory mechanisms through which a healthy plant-based dietary pattern is associated with lower risk of CHD and T2D (21, 22). In this study we observed consistently lower leptin concentrations with higher hPDI and lower uPDI cross-sectionally, and with increase in hPDI and decrease in uPDI longitudinally. Leptin is well known for not only inhibiting appetite by transmitting signals to hypothalamic cells (27), but also acting as a proinflammatory cytokine and stimulating the production of inflammatory mediators such as IL-1, IL-6, IL-12, and TNF (6). In the cross-sectional analysis, we also observed that sOB-R, which binds to leptin and regulates bioavailability of free leptin, had a significant positive association with hPDI, although this association was not observed in the longitudinal analysis. Similarly, plasma hsCRP concentrations were inversely associated with higher hPDI cross-sectionally, and with increase in hPDI and decrease in uPDI longitudinally, indicating lower inflammatory profiles among women who adhered to or improved the healthy plant-based diet. Further, our results suggest a possible inverse relationship between a healthy plant-based diet and leptin resistance, a metabolic phenotype in obese individuals characterized by substantially elevated leptin concentration due to the blocked leptin activity (28). Recent research on leptin resistance has revealed that CRP can competitively bind to sOB-R and directly inhibit the binding of leptin to sOB-R (29, 30). Interestingly, IL-6 showed a significant positive association only with uPDI change, but not with hPDI or hPDI change. It is possible that adherence to an unhealthy plant-based diet could have a particularly strong detrimental effect on IL-6, a marker of inflammation and insulin resistance (31).

The anti-inflammatory and anti–insulin resistance properties have been reported for the nutrients particularly associated with healthy plant foods. For example, in experimental models, polyphenols, such as procyanidin and cyanidin 3-glucoside found in fruits and vegetables, act as antioxidants inhibiting the production of proinflammatory cytokines, including CRP and IL-6 (32, 33). Anthocyanin and flavonol intakes have also been associated with a lower inflammation score that is calculated by 12 inflammatory biomarkers in US adults (34). In addition, dietary fiber intake has been inversely associated with hsCRP

### TABLE 1 Comparison of age-standardized characteristics between baseline (1996–1999) and follow-up (2010–2011) in the Nurses’ Health Study II

| Variable                              | Baseline       | Follow-up      | P       |
|---------------------------------------|----------------|----------------|---------|
| n                                     | 831            | 831            |         |
| Age at blood collection, y             | 45 ± 5         | 58 ± 4         | <0.001  |
| BMI, kg/m²                             | 24.6 ± 3.5     | 26.3 ± 4.7     | <0.001  |
| Weight, kg                            | 66.4 ± 10.2    | 70.7 ± 12.8    | <0.001  |
| Total energy intake, kcal/day          | 1886 ± 364     | 1756 ± 409     | <0.001  |
| Alcohol, g/day                        | 3.9 ± 5.8      | 6.2 ± 8.2      | <0.001  |
| Current smokers, %                    | 4.1            | 1.5            | <0.001  |
| Physical activity, MET-h/wk           | 17.8 ± 15.2    | 23.5 ± 22.2    | <0.001  |
| Postmenopausal, %                     | 20.6           | 72.1           | <0.001  |
| Current PMH use in postmenopausal, %  | 95.5           | 23.9           | <0.001  |
| Hypertension, %                       | 10.9           | 29.4           | <0.001  |
| Hypercholesterolemia, %               | 15.1           | 35.1           | <0.001  |
| hPDI                                  | 55.8 ± 4.8     | 57.8 ± 4.7     | <0.001  |
| uPDI                                  | 55.2 ± 5.7     | 54.3 ± 6.2     | 0.60    |
| Plasma biomarkers                     |                |                | <0.001  |
| Total adiponectin, μg/mL              | 7.0 [1.4]      | 7.4 [1.5]      | <0.001  |
| Leptin, ng/mL                         | 17.0 [1.8]     | 19.4 [2.0]     | <0.001  |
| Soluble leptin receptor, ng/mL        | 24.8 [1.2]     | 25.0 [1.3]     | <0.001  |
| Free leptin index                     | 0.7 [2.0]      | 0.8 [2.3]      | 0.001   |
| Insulin, μU/mL                        | 5.1 [1.8]      | 5.5 [1.7]      | 0.11    |
| RBP-4, μg/mL                          | 32.8 [1.2]     | 35.7 [1.2]     | <0.001  |
| High-sensitivity CRP, mg/L            | 0.99 [2.55]    | 1.03 [2.58]    | 0.10    |
| IL-6, pg/mL                           | 0.87 [1.54]    | 0.91 [1.57]    | 0.02    |

1Values are means ± SDs for continuous variables except plasma biomarkers, geometric means [geometric SDs] for all plasma biomarkers, and percentages for categorical variables; and are standardized to the age distribution of participants. P value is calculated based on paired t test (for continuous variables) or McNemar’s test (for binary variables). CRP, C-reactive protein; hPDI, healthful plant-based diet index; MET-h, metabolic equivalent task hours; PDI, overall plant-based diet index; PMH, postmenopausal hormone; RBP-4, retinol-binding protein-4; uPDI, unhealthy plant-based diet index.

2Values are not age adjusted.

3Free leptin index is defined as the ratio of leptin to soluble leptin receptor.
| Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 |
|-----------|-----------|-----------|-----------|-----------|
| Percentage difference/10-point higher indices (95% CIs) |
| P-trend |

### hPDI Baseline, n
- 165
- 159
- 205
- 146
- 156

Follow-up, n
- 172
- 137
- 202
- 158
- 162

Median (range)
- 46 (32–48)
- 51 (49–52)
- 55 (53–57)
- 59 (58–61)
- 65 (62–81)

### Adiponectin, ng/mL
- Multivariable: 6.9 (6.5, 7.3) to 7.4 (7.0, 7.9) 3.9 (12.6, 7.7) 0.005
- Multivariable + BMI: 6.8 (6.4, 7.2) to 7.3 (6.9, 7.7) 3.0 (0.4, 5.7) 0.025

### Leptin, ng/mL
- Multivariable: 20.0 (17.9, 22.3) to 15.9 (14.2, 17.7) <0.001
- Multivariable + BMI: 19.3 (17.7, 21.1) to 16.4 (15.0, 17.9) <0.001

### sOB-R, ng/mL
- Multivariable: 23.4 (22.5, 24.3) to 24.8 (23.9, 25.7) <0.001
- Multivariable + BMI: 23.4 (22.6, 24.2) to 24.3 (23.3, 25.1) <0.001

### Free leptin index
- Multivariable: 0.8 (0.7, 1.0) to 0.6 (0.6, 0.7) <0.001
- Multivariable + BMI: 0.8 (0.7, 0.9) to 0.7 (0.6, 0.8) <0.001

### Insulin, μU/mL
- Multivariable: 6.3 (5.7, 7.0) to 5.0 (4.5, 5.6) <0.001
- Multivariable + BMI: 6.2 (5.7, 6.9) to 4.8 (4.3, 5.3) <0.001

### RBP-4, μg/mL
- Multivariable: 36.5 (35.4, 37.7) to 36.4 (35.2, 37.6) 0.01
- Multivariable + BMI: 36.4 (35.2, 37.6) to 36.2 (35.0, 37.4) 0.90

### hsCRP, mg/L
- Multivariable: 1.21 (1.00, 1.45) to 0.87 (0.72, 1.05) <0.001
- Multivariable + BMI: 1.17 (0.98, 1.39) to 0.93 (0.78, 1.10) <0.001

### IL-6, pg/mL
- Multivariable: 0.93 (0.84, 1.02) to 0.87 (0.79, 0.96) 0.22
- Multivariable + BMI: 0.91 (0.83, 0.99) to 0.88 (0.81, 0.97) 0.75
| Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | Percentage difference/10-point higher indices (95% CIs) |
|-----------|-----------|-----------|-----------|-----------|-----------------------------------------------------|
| uPDI:     | Baseline, n | 64        | 118       | 156       | 207       | 286                                                 |
|           | Follow-up, n | 255       | 224       | 156       | 123       | 73                                                  |
| Median (range) | 40 (28–43) | 46 (44–48) | 50 (49–62) | 55 (52–57) | 61 (59–77) |
| Adiponectin, ng/mL | Multivariable | 7.4 (7.0, 7.9) | 7.4 (7.0, 7.9) | 7.0 (6.6, 7.5) | 7.1 (6.7, 7.6) | −2.4 (−4.8, 0.1) 0.06 |
|           | Multivariable | 7.2 (6.8, 7.7) | 7.3 (6.9, 7.7) | 6.9 (6.6, 7.3) | 7.0 (6.6, 7.4) | −1.6 (−4.0, 0.8) 0.19 |
| Leptin, ng/mL | Multivariable | 16.0 (14.4, 17.9) | 17.6 (15.9, 19.6) | 18.2 (16.4, 20.2) | 19.2 (17.3, 21.4) | 19.3 (17.3, 21.6) 9.2 (4.1, 14.5) <0.001 |
|           | Multivariable | 17.0 (15.5, 18.5) | 17.5 (16.1, 19.0) | 18.1 (16.5, 19.6) | 18.2 (16.7, 19.8) | 18.6 (17.0, 20.3) 4.4 (0.2, 8.6) 0.037 |
| sOB-R, ng/mL | Multivariable | 24.8 (23.9, 25.7) | 24.4 (23.5, 25.3) | 24.0 (23.1, 24.9) | 24.1 (23.2, 25.0) | 24.0 (23.1, 25.0) −1.3 (−3.0, 0.3) 0.11 |
|           | Multivariable | 24.3 (23.5, 25.2) | 24.2 (23.4, 24.5) | 23.8 (23.0, 24.6) | 24.1 (23.3, 24.9) | 24.0 (23.2, 24.9) −0.6 (−2.1, 1.0) 0.48 |
| Free leptin index | Multivariable | 0.5 (0.6, 0.7) | 0.7 (0.6, 0.8) | 0.8 (0.7, 0.9) | 0.8 (0.7, 0.9) | 0.8 (0.7, 0.9) |
|           | Multivariable | 0.7 (0.6, 0.8) | 0.7 (0.7, 0.8) | 0.8 (0.7, 0.8) | 0.7 (0.7, 0.8) | 0.8 (0.7, 0.8) 3.7 (−1.2, 9.9) 0.14 |
| Insulin, μU/mL | Multivariable | 5.0 (4.5, 5.6) | 5.6 (5.0, 6.2) | 5.6 (5.1, 6.2) | 5.6 (5.1, 6.2) | 5.7 (5.1, 6.3) 5.3 (0.2, 10.7) 0.043 |
|           | Multivariable | 5.1 (4.6, 5.6) | 5.7 (5.2, 6.2) | 5.7 (5.2, 6.3) | 5.7 (5.2, 6.3) | 5.7 (5.2, 6.3) 4.8 (0.1, 9.7) 0.048 |
| RBP-4, μg/mL | Multivariable | 35.5 (34.4, 36.7) | 36.2 (35.1, 37.3) | 35.8 (34.7, 36.9) | 36.6 (35.5, 37.8) | 36.6 (35.4, 37.8) 1.4 (−0.1, 3.0) 0.06 |
|           | Multivariable | 35.5 (34.4, 36.7) | 36.2 (35.0, 37.3) | 35.8 (34.8, 36.9) | 36.5 (35.4, 37.7) | 36.5 (35.4, 37.7) 1.3 (−0.2, 2.8) 0.09 |
| hsCRP, mg/L | Multivariable | 0.90 (0.75, 1.09) | 1.00 (0.84, 1.20) | 1.10 (0.92, 1.31) | 1.10 (0.91, 1.31) | 1.03 (0.85, 1.24) 6.7 (−2.0, 16.1) 0.14 |
|           | Multivariable | 0.90 (0.80, 1.14) | 1.03 (0.87, 1.21) | 1.12 (0.95, 1.33) | 1.08 (0.91, 1.28) | 1.02 (0.85, 1.21) 3.3 (−4.6, 11.8) 0.42 |
| IL-6, pg/mL | Multivariable | 0.86 (0.79, 0.95) | 0.89 (0.82, 0.98) | 0.89 (0.82, 0.98) | 0.90 (0.82, 0.99) | 0.90 (0.82, 0.99) 1.6 (−2.9, 6.3) 0.50 |
|           | Multivariable | 0.87 (0.79, 0.95) | 0.89 (0.82, 0.98) | 0.90 (0.82, 0.98) | 0.90 (0.82, 0.98) | 0.89 (0.81, 0.98) 1.1 (−3.1, 5.6) 0.61 |

1 Values are least squares geometric means (95% CIs) from linear mixed model to account for within-person correlation between the 2 blood-measurement time points. hPDI, healthful plant-based diet index; hsCRP, high-sensitivity C-reactive protein; RBP-4, retinol-binding protein-4; sOB-R, soluble leptin receptor; uPDI, unhealthful plant-based diet index.
2 Adjusted for age, time period, total energy intake, alcohol intake, smoking status, physical activity, menopausal status, postmenopausal hormone use, hypertension, and hypercholesterolemia.
3 Free leptin index is defined as the ratio of leptin to soluble leptin receptor.

1Values are least squares geometric means (95% CIs) from linear mixed model to account for within-person correlation between the 2 blood-measurement time points. hPDI, healthful plant-based diet index; hsCRP, high-sensitivity C-reactive protein; RBP-4, retinol-binding protein-4; sOB-R, soluble leptin receptor; uPDI, unhealthful plant-based diet index.
2Adjusted for age, time period, total energy intake, alcohol intake, smoking status, physical activity, menopausal status, postmenopausal hormone use, hypertension, and hypercholesterolemia.
3Free leptin index is defined as the ratio of leptin to soluble leptin receptor.
**TABLE 3** Percentage changes in plasma adiposity-associated biomarker concentrations across quintiles of an hPDI change and a uPDI change between 1995 and 2011 in the Nurses’ Health Study II

| Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | P-trend |
|------------|------------|------------|------------|------------|---------|
| n          | 174        | 174        | 146        | 181        | 156     |
| Median (range) | −9 (−20, −6) | −3 (−5, −2) | 0 (−1, 1)  | 4 (2, 6)   | 10 (7, 24) |
| **Adiponectin** |
| Multivariable | −2.3 (−10.1, 6.1) | 3.9 (−4.4, 12.9) | −0.3 (−8.5, 8.5) | 2.6 (−5.5, 11.4) | 7.4 (−15.5, 17.1) | 0.020 |
| Multivariable + Wt change | 1.8 (−6.0, 10.2) | 6.6 (−1.5, 15.4) | 3.2 (−8.1, 12.0) | 3.0 (−4.8, 11.5) | 7.9 (−6.6, 17.1) | 0.23 |
| **Leptin** |
| Multivariable  | 58.1 (34.9, 85.2) | 41.4 (20.7, 65.7) | 32.6 (17.7, 56.0) | 27.5 (8.9, 46.2) | 16.8 (−3.9, 37.6) | <0.001 |
| Multivariable + Wt change | 37.4 (20.2, 57.1) | 29.8 (13.6, 48.3) | 18.6 (3.4, 36.0) | 26.3 (10.7, 44.2) | 16.3 (13.3, 33.5) | 0.005 |
| **sOB-R** |
| Multivariable | −4.5 (−9.5, 0.9) | −2.2 (−7.4, 3.3) | −3.6 (−8.9, 1.9) | −1.9 (−7.1, 3.5) | −2.8 (−8.1, 2.9) | 0.44 |
| Multivariable + Wt change | −2.0 (−7.0, 3.2) | −0.6 (−5.6, 4.7) | −1.4 (−6.6, 4.0) | −1.8 (−6.7, 3.5) | −2.6 (−7.8, 2.8) | 0.65 |
| **Free leptin index** |
| Multivariable | 66.0 (35.8, 101.8) | 45.4 (19.8, 76.4) | 33.9 (9.7, 63.4) | 31.2 (8.2, 59.1) | 21.0 (−10.4, 47.9) | <0.001 |
| Multivariable + Wt change | 42.1 (20.2, 68.1) | 33.0 (12.5, 57.1) | 18.5 (−0.3, 40.7) | 31.2 (11.1, 54.8) | 21.0 (18.4, 43.9) | 0.038 |
| **Insulin** |
| Multivariable | 30.5 (8.8, 56.6) | 24.3 (3.8, 49.0) | 31.8 (9.5, 58.7) | 18.1 (−13.4, 41.3) | 17.3 (−27.4, 41.4) | 0.12 |
| Multivariable + Wt change | 20.7 (1.4, 43.8) | 18.8 (−0.1, 41.2) | 23.9 (3.7, 48.0) | 18.9 (0.2, 41.2) | 17.4 (−18.4, 40.3) | 0.72 |
| **RBP-4** |
| Multivariable | 13.1 (7.2, 19.3) | 10.5 (4.8, 16.5) | 10.0 (4.1, 16.2) | 12.6 (6.8, 18.8) | 10.8 (4.8, 17.1) | 0.62 |
| Multivariable + Wt change | 12.2 (6.4, 18.4) | 10.0 (4.1, 16.0) | 9.3 (3.5, 15.5) | 12.6 (6.8, 18.8) | 10.8 (4.9, 17.1) | 0.91 |
| **hsCRP** |
| Multivariable | 35.0 (3.1, 76.7) | 3.5 (−20.9, 35.3) | 1.4 (−230, 33.8) | −2.6 (−25.4, 27.2) | −22.4 (−41.3, 2.5) | <0.001 |
| Multivariable + Wt change | 20.2 (−7.3, 55.7) | −3.9 (−25.7, 24.3) | −7.6 (−29.1, 20.5) | −2.9 (−24.7, 25.5) | −22.2 (−40.4, 1.6) | <0.001 |
| **IL-6** |
| Multivariable | 14.7 (−2.4, 34.8) | 13.2 (−3.7, 33.0) | 21.1 (2.6, 42.9) | 8.8 (−7.4, 27.8) | 12.5 (−4.9, 32.9) | 0.61 |
| Multivariable + Wt change | 12.2 (−4.5, 31.9) | 11.8 (−4.8, 31.4) | 18.5 (0.4, 40.0) | 8.7 (−7.4, 27.8) | 12.5 (−4.7, 33.0) | 0.90 |

(Continued)
|                  | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | P-trend |
|------------------|------------|------------|------------|------------|------------|---------|
| **uPDI**         |            |            |            |            |            |         |
| n                | 157        | 174        | 148        | 192        | 160        |         |
| Median (range)   | -17 (-31, -14) | -11 (-13, -9) | -7 (-8, -6) | -3 (-5, -1) | 3 (0, 20)  |         |
| **Adiponectin**  |            |            |            |            |            |         |
| Multivariable    | 6.6        | 5.8        | 4.0        | 2.6        | 1.0        | 0.025   |
| Multivariable + Wt change | 7.6      | 6.8       | 5.0        | 3.7        | 2.5        | 0.21    |
| **Leptin**       |            |            |            |            |            |         |
| Multivariable    | 14.7       | 22.2       | 19.7       | 12.2       | 12.5       | <0.001  |
| Multivariable + Wt change | 14.7 | 22.2       | 19.7       | 12.2       | 12.5       | <0.001  |
| **sOB-R**        |            |            |            |            |            |         |
| Multivariable    | 0.7        | 1.7        | -3.8       | -2.7       | -1.4       | 0.018   |
| Multivariable + Wt change | 1.0      | 1.4        | -3.8       | -2.7       | -1.4       | 0.19    |
| **Free leptin index** | 14.7       | 26.7       | 53.9       | 44.4       | 31.3       | <0.001  |
| Multivariable + Wt change | 12.5 | 25.0       | 53.9       | 44.4       | 31.3       | <0.001  |
| **Insulin**      |            |            |            |            |            |         |
| Multivariable    | 26.8       | 19.5       | 18.9       | 15.3       | 12.0       | 0.53    |
| Multivariable + Wt change | 26.4 | 20.1       | 19.3       | 15.2       | 12.0       | 0.25    |
| **RBP-4**        |            |            |            |            |            |         |
| Multivariable    | 9.1        | 11.3       | 12.4       | 12.0       | 11.2       | 0.41    |
| Multivariable + Wt change | 9.0      | 11.5       | 12.6       | 12.0       | 11.2       | 0.25    |
| **hsCRP**        |            |            |            |            |            |         |
| Multivariable    | -17.0      | -4.9       | 15.6       | 16.5       | 24.6       | 0.001   |
| Multivariable + Wt change | -18.0   | -6.0       | 15.6       | 16.5       | 24.6       | 0.001   |
| **IL-6**         |            |            |            |            |            |         |
| Multivariable    | 1.6        | 7.0        | 13.5       | 17.2       | 28.1       | <0.001  |
| Multivariable + Wt change | 1.3     | 7.0        | 13.5       | 17.2       | 28.1       | <0.001  |

1 Values are adjusted least squares percentage changes (95% CIs) in plasma biomarker concentrations from general linear model. hPDI, healthful plant-based diet index; hsCRP, high-sensitivity C-reactive protein; RBP-4, retinol-binding protein-4; sOB-R, soluble leptin receptor; uPDI, unhealthful plant-based diet index; Wt, weight.

2 Adjusted for age at the first blood measurement, changes in total energy intake, alcohol intake, smoking status, physical activity, menopausal status, postmenopausal hormone use, hypertension, hypercholesterolemia, baseline BMI, baseline corresponding plant-based diet indices, and baseline corresponding biomarker concentrations.

3 Free leptin index is defined as the ratio of leptin to soluble leptin receptor.
stress and inflammation (37). Saturated fat can increase the healthy plant foods, and has been associated with elevated oxidative unhealthful plant-based index. RBP-4, retinol-binding protein-4; sOB-R, soluble leptin receptor; uPDI, high-sensitivity C-reactive protein; PDI, overall plant-based diet index; hypercholesterolemia. hPDI, healthful plant-based diet index; hsCRP, menopausal status, postmenopausal hormone use, hypertension, and total energy intake, alcohol intake, smoking status, physical activity, diabetes, and inflammatory biomarkers. The Mediterranean diet is characterized by a high intake of fruits, vegetables, legumes, nuts, and fish, and a low intake of red meat, dairy products, and refined carbohydrates. The opposite associations we observed between a healthy diet and adiponectin, leptin, and insulin. Moreover, only in our study was there a significant association between healthy diet and hsCRP, even after adjusting for BMI or weight change. Because of the emerging evidence of associations with obesity-related diseases and inflammation (45–47), when compared with the AHEI-2010, the hPDI additionally accounts for lowered intake of less healthy plant-based food, such as refined grains, potatoes, and sweets, possibly contributing to a stronger association between hPDI and hsCRP. In this study, the PDI had no significant associations with adiposity-associated biomarkers, either cross-sectionally or longitudinally. The result is consistent with previous publications showing that a hPDI has a stronger association with a reduced risk of developing CHD and T2D (21, 22), and emphasizes the importance of differentiating the quality of plant-based food. The opposite associations we observed between hPDI and uPDI for multiple inflammatory and metabolic biomarkers corroborate the recommendation that increasing the intake of healthy plant foods and reducing the intake of less healthy plant foods simultaneously would be essential for the prevention of cardiometabolic diseases.

Several limitations should be noted. First, the participants were predominantly Caucasian registered nurses without CVD and T2D. Therefore, translating results to the general population should be done with caution. Second, although we have controlled for multiple important lifestyle factors in the analyses, the possibility of residual confounding cannot be excluded. Third, our dietary assessment was based on self-reported questionnaires, which could introduce measurement errors. However, the consistency of the strong associations between diet indices and biomarkers in both cross-sectional and longitudinal analyses suggests that the observed associations were unlikely to be entirely explained by residual confounding or measurement errors. Further, the potential impact of long-term blood storage on the biomarker stability needs additional studies, which might reveal nondifferential measurement errors and likely attenuate the observed associations.

In conclusion, adherence to a healthful plant-based diet is associated with favorable changes in adiposity-related inflammatory and metabolic biomarkers even after adjustment for weight change. Our results provide evidence for biological mechanisms underlying the inverse associations between a healthful plant-based diet and obesity-related diseases, and support current recommendations to increase intake of healthy plant foods, while reducing intake of less healthy plant foods for improved health outcomes.

Acknowledgments

The authors’ responsibilities were as follows—MYB, AS, FBH, and TH: designed and conducted the study; AS: developed plant-based diet indices; MYB: performed the statistical analyses and drafted the manuscript; MYB, AS, FBH, and TH: interpreted the data, critically revised the manuscript, and had full responsibility for the analyses and interpretation of the data;
MYB: full access to all study data; and all authors: read and approved the final manuscript.

References

1. Hu Y, Buthapathiraju SN, de Koning L, Hu FB. Duration of obesity and overweight and risk of type 2 diabetes among US women. Obesity. 2014;22:2267–73.

2. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990;322:882–9.

3. Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm ER, Danaei G. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet. 2014;383:970–83.

4. Abdelala M, le Roux CW, Dorchy NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;5:161.

5. Lammert A, Kiess W, Bottmer A, Glasow A, Kratzsch J. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–95.

6. Carbone F, La Rocca C, Materese G. Immunological functions of leptin and adiponectin. Biochimie. 2012;94:2082–8.

7. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–95.

8. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoaka K, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.

9. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kurryama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296–301.

10. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354:2522–63.

11. Lemieux I, Pascot A, Prud’homme D, Almeras N, Bogaty P, Nadeau A, Bergeron J, Després JP. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21:961–7.

12. Carrière A, Lemieux I, Almeras N, Tremblay A, Bergeron J, Després JP. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-α in men. J Clin Endocrinol Metab. 2008;93:1931–8.

13. Huang T, Yang B, Zheng J, Li G, Wahlgqvist ML, Li D. Cardiovascular disease mortality and cancer incidence in vegetarians: a meta-analysis and systematic review. Ann Nutr Metab. 2012;60:233–40.

14. Tonstad S, Stewart O, Kda O, Batech M, Herring RP, Fraser GE. Vegetarian diets and incidence of diabetes in the Adventist Health Study-2. Nutr Metab Cardiovasc Dis. 2013;23:292–9.

15. Kwok CS, Umar S, Myint PK, Mamas MA, Loke YK. Vegetarian diet, Seventh Day Adventists and risk of cardiovascular mortality: a systematic review and meta-analysis. Int J Cardiol. 2014;174:680–6.

16. Yokoyama N, Nishimura K, Barnard ND, Takegami M, Watanabe M, Sekikawa A, Okamura T, Miyamoto Y. Vegetarian diets and blood pressure: a meta-analysis. JAMA Intern Med. 2014;174:577–87.

17. Huang RY, Huang CC, Hu FB, Chavarro JE. Vegetarian diets and weight reduction: a meta-analysis of randomized controlled trials. J Gen Intern Med. 2013;28:1091–10.

18. Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P, Brand-Miller JC. Glycemic index, glycemic load, and chronic disease risk—a meta-analysis of observational studies. Am J Clin Nutr. 2008;87:627–37.

19. Huang C, Huang J, Tian Y, Yang X, Gu D. Sugar sweetened beverages consumption and risk of coronary heart disease: a meta-analysis of prospective studies. Atherosclerosis. 2014;234:11–6.

20. Yang Q, Zhang Z, Gregg EW, Flanders WD, Merritt R, Hu FB. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med. 2014;174:516–24.

21. Satija A, Buthapathiraju SN, Rimm EB, Spiegelman D, Chiuve SE, Borglum L, Willett WC, Manson JE, Sun Q, Hu FB. Plant-based dietary patterns and incidence of type 2 diabetes in US men and women: results from three prospective cohort studies. PLoS Med. 2016;13:e1002039.

22. Satija A, Buthapathiraju SN, Spiegelman D, Chiuve SE, Manson JE, Willett W, Rexrode KM, Rimm EB, Hu FB. Healthful and unhealthy plant-based diets and the risk of coronary heart disease in U.S. adults. J Am Coll Cardiol. 2017;70:411–22.

23. Huang T, Tobias DK, Hruby A, Rifai N, Tworoger SS, Hu FB. An increase in dietary quality is associated with favorable plasma biomarkers of the brain-adipose axis in apparently healthy US women. J Nutr. 2016;146:1011–8.

24. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Wrohnsa J, Hennekens CH, Speizer FE. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985;122:51–65.

25. Salvini S, Hunter DJ, Sampson L, Stampfer MJ, Colditz GA, Rosner B, Willett WC. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol. 1989;18:858–67.

26. Yannakoulia M, Yannakouris N, Bluhu S, Matalas AL, Klimes-Zacu D, Mntzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy. J Clin Endocrinol Metab. 2003;88:1730–6.

27. Friedman JM, Halaas JL. Leptin and the regulation of body weight in animals. Nature. 1998;395:763–70.

28. Bjorbaek C, El-Haschimi K, Frantz JD, Fler JS. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem. 1999;274:3059–65.

29. Chen K, Li F, Li J, Cai H, Strom S, Bisello A, Kelley DE, Friedman-Einat M, Skibinski GA, McCrory MA, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006;12:425–32.

30. Sudhakar M, Silambamban S, Chandras A, Prabhakaran AA, Ramakrishnan R. C-reactive protein (CRP) and leptin receptor in obesity: binding of monomeric CRP to leptin receptor. Front Immunol. 2018;9:1167.

31. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002;51:3391–9.

32. Terra X, Montagut G, Bustos M, Lloipiz N, Ardevol A, Blade C, Fernandez-Larrea J, Pujadas G, Salvado J, Arola L, et al. Grape-seed procyanidins prevent low-grade inflammation by modulating cytokine expression in rats fed a high-fat diet. J Nutr Biochem. 2009;20:210–8.

33. Guo H, Xia M, Zou T, Ling W, Zhong R, Zhang W, Caidin 3-glucoside attenuates obesity-associated insulin resistance and hepatic steatosis in high-fat diet-fed and db/db mice via the transcription factor FoxO1. J Nutr Biochem. 2012;23:349–60.

34. Cassidy A, Rogers G, Peterson JJ, Dwyer JT, Lin H, Jacques PF. Higher dietary anthocyanin and flavonol intakes are associated with anti-inflammatory effects in a population of US adults. Am J Clin Nutr. 2015;102:172–81.

35. Butcher JL, Beckstrand RL. Fiber’s impact on high-sensitivity C-reactive protein levels in cardiovascular disease. J Am Acad Nutr Pract. 2010;22:566–72.

36. Ma Y, Hebert JR, Li W, Bertone-Johnson ER, Olenziki D, Pagoto SL, Tinker L, Rosal MC, Ockene IS, Ockene JK, et al. Association between dietary fiber and markers of systemic inflammation in the Women’s Health Initiative Observational Study. Nutrition. 2008;24:941–9.

37. Lopez-Garcia E, Schulze MB, Mein JD, Manson JE, Ruffin EB, Willett WC. The Mediterranean diet: science and practice. Public Health Nutr. 2006;9:105–10.
41. Esposito K, Marfella R, Cioccola M, Di Palo C, Giugliano F, Giugliano G, D’Armiento M, D’Andrea F, Giugliano D. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004;292:1440–6.

42. Maiorino MI, Bellastella G, Petrizzo M, Scappaticcio L, Giugliano D, Esposito K. Mediterranean diet cools down the inflammatory milieu in type 2 diabetes: the MEDITA randomized controlled trial. Endocrine. 2016;54:634–41.

43. Sacks FM, Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Bray GA, Vogt TM, Cutler JA, Windhauser MM, et al. A dietary approach to prevent hypertension: a review of the Dietary Approaches to Stop Hypertension (DASH) Study. Clin Cardiol. 1999;22:i6–10.

44. Soltani S, Chitsazi MJ, Salehi-Abargouei A. The effect of Dietary Approaches to Stop Hypertension (DASH) on serum inflammatory markers: a systematic review and meta-analysis of randomized trials. Clin Nutr. 2018;37:542–50.

45. Masters RC, Liese AD, Wagenknecht LE, Hanley AJ. Whole and refined grain intakes are related to inflammatory protein concentrations in human plasma. J Nutr. 2010;140:587–94.

46. Naruszewicz M, Zapolska-Downar D, Kowalska A, Nowicka G, Kolodziejczyk A. Dietary intake of potato chips in humans increases the production of reactive oxygen radicals by leukocytes and decreases plasma C-reactive protein: a pilot study. Am J Clin Nutr. 2009;89:773–7.

47. Della Corte KW, Perrar I, Penczynski KJ, Schwingshackl L, Herder C, Buyken AE. Effect of dietary sugar intake on biomarkers of subclinical inflammation: a systematic review and meta-analysis of intervention studies. Nutrients 2018;10:E606.